SS-31 is typically administered via injection and is being studied in various clinical trials. It works by binding to the inner mitochondrial membrane, where it exerts protective effects against mitochondrial dysfunction, improves energy metabolism, and enhances the health and function of muscle tissue
Tesamorelin is administered via subcutaneous injection, typically once daily. The dosage depends on individual needs and should be determined by a healthcare provider. It works by binding to GHRH receptors in the pituitary gland, promoting the release of growth hormone.